-
Je něco špatně v tomto záznamu ?
Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic
M. Tánczosová, M. Kojanová, M. Arenbergerová, P. Arenberger, T. Doležal, D. Štrosová, J. Fialová, S. Gkalpakiotis
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
Digitální knihovna NLK
Zdroj
NLK
Free Medical Journals
od 2004
ProQuest Central
od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
od 1993
PubMed
35421298
DOI
10.21101/cejph.a6885
Knihovny.cz E-zdroje
- MeSH
- atopická dermatitida * diagnóza farmakoterapie MeSH
- dospělí MeSH
- humanizované monoklonální protilátky MeSH
- imunoglobulin E terapeutické užití MeSH
- kvalita života * MeSH
- lidé MeSH
- retrospektivní studie MeSH
- stupeň závažnosti nemoci MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVES: The aim of the study was to assess the effectiveness and safety of dupilumab therapy in patients with moderate-to-severe atopic dermatitis (AD) in a real-life Czech bicentric cohort. METHODS: We retrospectively analysed 50 patients with moderate-to-severe AD treated with dupilumab in two centres in the Czech Republic. Baseline characteristics, the Eczema Area and Severity Index (EASI) score and Dermatology Life Quality Index (DLQI) were collected at baseline and each 3 following months. The proportion of patients achieving EASI50, EASI75, EASI90 and EASI100 were analysed. Levels of immunoglobulin E (IgE) were collected before and after 6 and 12 months of therapy. Adverse events were recorded as well. RESULTS: Thirty-two men and 18 women with mean body mass index (BMI) of 25.7 were enrolled in our analysis. The mean age of the patients was 37.6 years and the mean time from diagnosis until the initiation of dupilumab therapy was 35.0 years. After 4 months, EASI75 was achieved by 75.7%, out of which 40.5% achieved EASI90 and 10.8% achieved complete clearance. Improvement continued with time, and the proportion of patients with EASI90 increased to 71.4% at the 6th month and at the 12th month of therapy the EASI90 was 65.2%. EASI100 was achieved by 14.3% and 13.0% at the 6th and 12th month, respectively. A marked reduction was observed in the DLQI and also in IgE levels. EASI responses were independent of BMI. No new safety issues were identified. Adverse events were experienced by 44% (22/50) of the patients and they were all mild in intensity. Conjunctivitis and herpes simplex virus infection were the most common adverse events. CONCLUSION: Our results confirmed the effectiveness and safety of dupilumab in a real-life setting in adult patients with moderate-to-severe AD in the Czech Republic. Dupilumab was well-tolerated and resulted in a significant clinical improvement in combination with improvement of quality of life.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22013080
- 003
- CZ-PrNML
- 005
- 20220622160510.0
- 007
- ta
- 008
- 220504s2022 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a6885 $2 doi
- 035 __
- $a (PubMed)35421298
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Tánczosová, Milena $u Department of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic $7 xx0234961
- 245 10
- $a Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic / $c M. Tánczosová, M. Kojanová, M. Arenbergerová, P. Arenberger, T. Doležal, D. Štrosová, J. Fialová, S. Gkalpakiotis
- 520 9_
- $a OBJECTIVES: The aim of the study was to assess the effectiveness and safety of dupilumab therapy in patients with moderate-to-severe atopic dermatitis (AD) in a real-life Czech bicentric cohort. METHODS: We retrospectively analysed 50 patients with moderate-to-severe AD treated with dupilumab in two centres in the Czech Republic. Baseline characteristics, the Eczema Area and Severity Index (EASI) score and Dermatology Life Quality Index (DLQI) were collected at baseline and each 3 following months. The proportion of patients achieving EASI50, EASI75, EASI90 and EASI100 were analysed. Levels of immunoglobulin E (IgE) were collected before and after 6 and 12 months of therapy. Adverse events were recorded as well. RESULTS: Thirty-two men and 18 women with mean body mass index (BMI) of 25.7 were enrolled in our analysis. The mean age of the patients was 37.6 years and the mean time from diagnosis until the initiation of dupilumab therapy was 35.0 years. After 4 months, EASI75 was achieved by 75.7%, out of which 40.5% achieved EASI90 and 10.8% achieved complete clearance. Improvement continued with time, and the proportion of patients with EASI90 increased to 71.4% at the 6th month and at the 12th month of therapy the EASI90 was 65.2%. EASI100 was achieved by 14.3% and 13.0% at the 6th and 12th month, respectively. A marked reduction was observed in the DLQI and also in IgE levels. EASI responses were independent of BMI. No new safety issues were identified. Adverse events were experienced by 44% (22/50) of the patients and they were all mild in intensity. Conjunctivitis and herpes simplex virus infection were the most common adverse events. CONCLUSION: Our results confirmed the effectiveness and safety of dupilumab in a real-life setting in adult patients with moderate-to-severe AD in the Czech Republic. Dupilumab was well-tolerated and resulted in a significant clinical improvement in combination with improvement of quality of life.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a humanizované monoklonální protilátky $7 D061067
- 650 12
- $a atopická dermatitida $x diagnóza $x farmakoterapie $7 D003876
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobulin E $x terapeutické užití $7 D007073
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kojanová, Martina $u Department of Dermatovenereology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0106209
- 700 1_
- $a Arenbergerová, Monika, $u Department of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic $d 1971- $7 xx0074761
- 700 1_
- $a Arenberger, Petr, $u Department of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic $d 1958- $7 nlk19990072992
- 700 1_
- $a Doležal, Tomáš $u Value Outcomes, Prague, Czech Republic $7 _AN113729
- 700 1_
- $a Štrosová, Daniela $u Value Outcomes, Prague, Czech Republic $7 xx0262431
- 700 1_
- $a Fialová, Jorga $u Department of Dermatovenereology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0141491
- 700 1_
- $a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic $7 xx0094696
- 773 0_
- $w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 30, č. 1 (2022), s. 46-50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35421298 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y p $z 0
- 990 __
- $a 20220504 $b ABA008
- 991 __
- $a 20220622160505 $b ABA008
- 999 __
- $a ok $b bmc $g 1806518 $s 1164288
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 30 $c 1 $d 46-50 $e - $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
- LZP __
- $b NLK138 $a Pubmed-20220504
